Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Mar 15.

Published in final edited form as: Mutat Res. 2011 Feb 16;708(1-2):21–27. doi: 10.1016/j.mrfmmm.2011.01.002

Cell viability did not change in the UV20^ERCC1_C and UV20^ERCC1_T cell lines. The parental cell line UV20, empty vector transfected control cell line, and ERCC1 cDNA with either allele of 500 C>T transfected cell line UV20^ERCC1_C and UV20^ERCC1_T were treated with cisplatin (0, 2.56×10⁻⁶, 6.40×10⁻⁵, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 µg/µl), carboplatin (0, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 and 1.00 µg/µl) and oxaliplatin (0, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 and 1.00 µg/µl). The cell cytotoxicity was tested by CCK-8 and CellTiter-Blue assayes. Only the results from CCK-8 assay for carboplatin and oxaliplatin are shown. Data are mean ± SD obtained from three independent experiments with triplicates in each experiment.

Cell viability did not change in the UV20^ERCC1_C and UV20^ERCC1_T cell lines. The parental cell line UV20, empty vector transfected control cell line, and ERCC1 cDNA with either allele of 500 C>T transfected cell line UV20^ERCC1_C and UV20^ERCC1_T were treated with cisplatin (0, 2.56×10⁻⁶, 6.40×10⁻⁵, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 µg/µl), carboplatin (0, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 and 1.00 µg/µl) and oxaliplatin (0, 3.2×10⁻⁴, 1.6×10⁻³, 8×10⁻², 4×10⁻², 0.2 and 1.00 µg/µl). The cell cytotoxicity was tested by CCK-8 and CellTiter-Blue assayes. Only the results from CCK-8 assay for carboplatin and oxaliplatin are shown. Data are mean ± SD obtained from three independent experiments with triplicates in each experiment.